Skip to content

Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition

Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01762943
Enrollment
36
Registered
2013-01-08
Start date
2013-08-31
Completion date
2016-10-13
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Depression

Brief summary

Understanding the neural and biological mechanisms by which reproductive hormones influence mood is critically important for public health given that postpartum depression (PPD) is the leading cause of morbidity and mortality associated with childbirth and has negative effects on infants. Using a hormone-withdrawal challenge to precipitate mood symptoms will improve our ability to identify the biological mechanisms underlying both the triggering of and susceptibility to depressive disorders in women; and will permit the prediction of those at risk for PPD and other reproductive-related mood disorders.

Detailed description

Affective disorders, such as PPD and other reproductive-related mood disorders, are common and constitute a significant burden for women, children, and society. However, little is known about the neurobiological mechanisms underlying depressive disorders in women. The long-term goal of this research is to 1) advance our understanding of the biological mechanisms underlying both the triggering of and susceptibility to depressive disorders in women; and 2) permit the prediction of those at risk for PPD. The objective of the current project is to examine whether those with a past episode of PPD (at high risk for recurrence) show differences in emotional arousal and reward processing domains relative to healthy control women (without a history of PPD) under baseline and hormone withdrawal-precipitated conditions. The central hypothesis is that reproductive hormone changes are associated with dysregulation of the neural circuits underlying emotional arousal and reward processing and consequent depressive symptoms in high-risk women. The rationale for the proposed study is that employing a scaled down model of puerperal hormonal events in high-risk women permits the identification of a group of individuals homogeneous for reproductive related affective dysfunction and, hence, the best opportunity for disentangling the specific changes in brain function due to reproductive hormones from those accompanying reproductive hormone-precipitated affective dysfunction. Moreover, identifying a neurophysiologic biomarker for hormone-related affective dysfunction provides a clear pathway for examining mechanisms of susceptibility to affective dysfunction across disorders. The investigators plan to accomplish the objectives of this application by pursuing the following specific aims: 1) to assess the effects of simulated postpartum reproductive hormone withdrawal, compared to baseline, on corticolimbic circuit activation in high-risk and control women; and 2) to examine the effects of reproductive hormone withdrawal, compared to baseline, on reward circuit activation in high-risk and control women. An additional exploratory aim is to identify a neural biomarker, characterized by corticolimbic and reward circuit dysfunction, that can be used to predict the onset of PPD. The proposed study involves experimentally manipulating reproductive hormones in euthymic women to create a scaled down version of the changes that occur at the puerperium. This endocrine manipulation paradigm will be used to examine the neurocircuitry underlying the regulation of affect and reward processing under baseline and hormone withdrawal-precipitated conditions among women who are expected to experience hormone-related affective dysregulation (n=15) and controls (n=15). In short, the investigators expect that relative to baseline, high-risk women will show greater dysregulation in neural circuits responsible for emotion processing and reward processing during hormone withdrawal than low-risk control women. The expected outcome of this research is the identification of neural circuits underlying both the susceptibility to and mediation of hormone-related affective dysfunction. Understanding these neurobiological mechanisms will subsequently improve the ability to identify those at risk for PPD, which may strengthen prevention efforts and ultimately prevent the deleterious effects of maternal depression on offspring.

Interventions

DRUGLeuprolide Acetate

All subjects will receive one IM injection (3.75 mg) each month for four months.

DRUGMicronized estradiol

All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.

DRUGProgesterone

All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.

Sponsors

Foundation of Hope, North Carolina
CollaboratorOTHER
North Carolina Translational and Clinical Sciences Institute
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
National Alliance for Research on Schizophrenia and Depression
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
22 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

Group 1: Women with a history of PPD 1. A history of a major depression episode that occurred within two months of childbirth (as determined by a SCID interview) and remitted at least one year prior to enrollment in the study; 2. has been well for a minimum of one year; 3. a regular menstrual cycle for at least three months; 4. age 22-50; 5. not pregnant, not lactating and in good medical health; 6. medication free (not including birth control pills; participants may opt to temporarily discontinue birth control pills to participate); 7. no history of puerperal suicide attempts or psychotic episodes requiring hospitalization. Group 2: Healthy Controls 1\) Controls will meet all inclusion criteria specified above except they must not have any past or present Axis I diagnosis or evidence of menstrually related mood disorders. A structured clinical interview (SCID) will be administered to all women prior to study entry. Any woman with a current axis I psychiatric diagnosis will be excluded from participating in this protocol.

Exclusion criteria

Patients will not be permitted to enter this protocol if they have important clinical or laboratory abnormalities including any of the following: * current axis I psychiatric diagnosis * endometriosis; * undiagnosed enlargement of the ovaries; * liver disease; * breast cancer; * a history of blood clots in the legs or lungs; * undiagnosed vaginal bleeding; * porphyria; * diabetes mellitus; * malignant melanoma; * gallbladder or pancreatic disease; * heart or kidney disease; * cerebrovascular disease (stroke); * cigarette smoking; * a history of suicide attempts or psychotic episodes requiring hospitalization; * recurrent migraine headaches; * pregnancy (patients will be warned not to become pregnant during the study and will be required to agree to employ barrier contraceptive methods); * pregnancy-related medical conditions such as hyperemesis, pre-toxemia and toxemia, deep vein thrombosis (DVT) and bleeding diathesis; Any woman with a first degree relative (immediate family) with either ovarian cancer, premenopausal breast cancer or breast cancer presenting in both breasts or any woman who has multiple family members (greater than three relatives) with postmenopausal breast cancer will also be excluded from participating in this protocol; Any woman meeting the Stages of Reproductive Aging Workshop Criteria (STRAW) for perimenopause will be excluded from participation. Specifically, we will exclude any woman with an elevated plasma follicle stimulating hormone (FSH) level (\> 14 IU/L) and with menstrual cycle variability of \> 7 days different from their normal cycle length.

Design outcomes

Primary

MeasureTime frameDescription
Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z Statisticbaseline and hormone withdrawalThe primary outcome measure was functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. The BOLD response was examined within the nucleus accumbens, a brain region that responds to monetary rewards. The z statistic represents the maximum contrast between win versus non-win outcomes during the MID task in the nucleus accumbens, averaged across the participants in each group. The mean BOLD response ranged from z=1.7 to 2.3; higher z scores indicate greater activation of the nucleus accumbens during reward. Individual z scores were generated using the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library (FSL), which is a library of brain imaging analysis tools for fMRI.

Secondary

MeasureTime frameDescription
Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria ScoreAssessed at baseline and post-treatmentThe IDAS Dysphoria Scale consists of 10 items and uses a 5-point Likert-type scale, ranging from 1 to 5 with 1 indicating not at all and 5 indicating extremely. As such, the range of possible scores is 10 to 50. The Dysphoria scale includes items assessing feelings of depression, inadequacy, psychomotor agitation, guilt, discouragement, anhedonia, poor concentration, difficulty with decision-making, psychomotor retardation, and worry. Higher scores indicate greater dysphoria.

Countries

United States

Participant flow

Recruitment details

Out of 3,341 completed screening forms, 406 women appeared initially eligible. 54 were responsive, interested in participating, and eligible to enroll based on pre-screening (unmedicated, without current psychiatric illness or chronic health conditions).

Pre-assignment details

Of the 54 women who were recruited to participate, 18 did not meet our eligibility criteria during the extensive safety screening phase because of medical conditions found upon exam, use of medications, family history of reproductive cancer, history of pregnancy-related medical condition, and lack of compliance with the screening protocol.

Participants by arm

ArmCount
Women With Postpartum Depression (PPD)
4 monthly IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo. Leuprolide Acetate: All subjects will receive one IM injection (3.75 mg) each month for four months. Micronized estradiol: All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day. Progesterone: All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
19
Women Without Any Psychiatric History (Control)
4 monthly IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo. Leuprolide Acetate: All subjects will receive one IM injection (3.75 mg) each month for four months. Micronized estradiol: All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day. Progesterone: All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
17
Total36

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision11
Overall StudyProtocol Violation10
Overall StudyWithdrawal by Subject21

Baseline characteristics

CharacteristicWomen With Postpartum Depression (PPD)Women Without Any Psychiatric History (Control)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
19 Participants17 Participants36 Participants
Age, Continuous35.053 years
STANDARD_DEVIATION 4.916
36.294 years
STANDARD_DEVIATION 4.224
35.639 years
STANDARD_DEVIATION 4.58
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants0 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants17 Participants33 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants0 Participants2 Participants
Race (NIH/OMB)
Asian
0 Participants3 Participants3 Participants
Race (NIH/OMB)
Black or African American
3 Participants3 Participants6 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
14 Participants11 Participants25 Participants
Region of Enrollment
United States
19 Participants17 Participants36 Participants
Sex: Female, Male
Female
19 Participants17 Participants36 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 190 / 17
other
Total, other adverse events
12 / 1911 / 17
serious
Total, serious adverse events
0 / 190 / 17

Outcome results

Primary

Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z Statistic

The primary outcome measure was functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. The BOLD response was examined within the nucleus accumbens, a brain region that responds to monetary rewards. The z statistic represents the maximum contrast between win versus non-win outcomes during the MID task in the nucleus accumbens, averaged across the participants in each group. The mean BOLD response ranged from z=1.7 to 2.3; higher z scores indicate greater activation of the nucleus accumbens during reward. Individual z scores were generated using the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library (FSL), which is a library of brain imaging analysis tools for fMRI.

Time frame: baseline and hormone withdrawal

Population: Of the 36 women who enrolled in the study, 6 were withdrawn prior to the second fMRI session. For the purpose of this group x time analysis, their data have been excluded. In addition, one participant had significant motion artifact (\>4mm) during one run of the MID, and as such, her data were excluded from the analyses.

ArmMeasureGroupValue (MEAN)Dispersion
Women With a History of Postpartum Depression (PPD)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticLeft Nucleus Acc Baseline2.3 z scoreStandard Deviation 1.13
Women With a History of Postpartum Depression (PPD)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticLeft Nucleus Acc Withdrawal2.1 z scoreStandard Deviation 1.2
Women With a History of Postpartum Depression (PPD)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticRight Nucleus Acc Baseline2.2 z scoreStandard Deviation 1.12
Women With a History of Postpartum Depression (PPD)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticRight Nucleus Acc Withdrawal2.3 z scoreStandard Deviation 1.05
Women Without Any Psychiatric History (Control)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticRight Nucleus Acc Withdrawal2.0 z scoreStandard Deviation 0.83
Women Without Any Psychiatric History (Control)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticLeft Nucleus Acc Baseline2.0 z scoreStandard Deviation 0.99
Women Without Any Psychiatric History (Control)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticRight Nucleus Acc Baseline2.0 z scoreStandard Deviation 1.09
Women Without Any Psychiatric History (Control)Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z StatisticLeft Nucleus Acc Withdrawal1.7 z scoreStandard Deviation 0.69
p-value: 0.27repeated measures ANOVA
Secondary

Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria Score

The IDAS Dysphoria Scale consists of 10 items and uses a 5-point Likert-type scale, ranging from 1 to 5 with 1 indicating not at all and 5 indicating extremely. As such, the range of possible scores is 10 to 50. The Dysphoria scale includes items assessing feelings of depression, inadequacy, psychomotor agitation, guilt, discouragement, anhedonia, poor concentration, difficulty with decision-making, psychomotor retardation, and worry. Higher scores indicate greater dysphoria.

Time frame: Assessed at baseline and post-treatment

Population: Of the 36 women who enrolled in the study, 6 (4 PPD, 2 controls) were withdrawn prior to the second fMRI session. For the purpose of this group x time analysis, their data have been excluded. All 30 subjects who completed the protocol were included in this analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Women With a History of Postpartum Depression (PPD)Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria ScoreIDAS Dysphoria Baseline11.4 units on a scaleStandard Deviation 2.2
Women With a History of Postpartum Depression (PPD)Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria ScoreIDAS Dysphoria Withdrawal15.7 units on a scaleStandard Deviation 8.29
Women Without Any Psychiatric History (Control)Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria ScoreIDAS Dysphoria Baseline12.7 units on a scaleStandard Deviation 3.08
Women Without Any Psychiatric History (Control)Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria ScoreIDAS Dysphoria Withdrawal11.1 units on a scaleStandard Deviation 1.34
p-value: 0.018repeated measures ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026